Evidence map›Paper›PMID 37450198›Full record

ArticleTherapeutic innovation & regulatory science2023

Application of Statistical Methods for Central Statistical Monitoring and Implementations on the German Multiple Sclerosis Registry.

Firas Fneish, David Ellenberger, Niklas Frahm, Alexander Stahmann, Gerhard Fortwengel, Frank Schaarschmidt

Abstract read
In one paragraph

Article in Therapeutic innovation & regulatory science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Firas FneishDepartment of Biostatistics, Institute of Cell Biology and Biophysics, Leibniz University Hannover, Herrenhäuser Straße 2, 30419, Hannover, Germany. fneish@cell.uni-hannover.de.ORCID 0000-0001-8279-8463
David EllenbergerGerman MS-Register, MS Forschungs- und Projektentwicklungs- gGmbH [MSFP], Krausenstraße 50, 30171, Hannover, Germany.ORCID 0000-0002-2274-5025
Niklas FrahmGerman MS-Register, MS Forschungs- und Projektentwicklungs- gGmbH [MSFP], Krausenstraße 50, 30171, Hannover, Germany.ORCID 0000-0002-4655-774X
Alexander StahmannGerman MS-Register, MS Forschungs- und Projektentwicklungs- gGmbH [MSFP], Krausenstraße 50, 30171, Hannover, Germany.ORCID 0000-0001-5308-105X
Gerhard FortwengelFaculty III-Media, Information, and Design, Hochschule Hannover, 30539, Hannover, Germany.
Frank SchaarschmidtDepartment of Biostatistics, Institute of Cell Biology and Biophysics, Leibniz University Hannover, Herrenhäuser Straße 2, 30419, Hannover, Germany.ORCID 0000-0002-6599-3803

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monitoring of clinical trials is a fundamental process required by regulatory agencies. It assures the compliance of a center to the required regulations and the trial protocol. Traditionally, monitoring teams relied on extensive on-site visits and source data verification. However, this is costly, and the outcome is limited. Thus, central statistical monitoring (CSM) is an additional approach recently embraced by the International Council for Harmonisation (ICH) to detect problematic or erroneous data by using visualizations and statistical control measures. Existing implementations have been primarily focused on detecting inlier and outlier data. Other approaches include principal component analysis and distribution of the data. Here we focus on the utilization of comparisons of centers to the Grand mean for different model types and assumptions for common data types, such as binomial, ordinal, and continuous response variables. We implement the usage of multiple comparisons of single centers to the Grand mean of all centers. This approach is also available for various non-normal data types that are abundant in clinical trials. Further, using confidence intervals, an assessment of equivalence to the Grand mean can be applied. In a Monte Carlo simulation study, the applied statistical approaches have been investigated for their ability to control type I error and the assessment of their respective power for balanced and unbalanced designs which are common in registry data and clinical trials. Data from the German Multiple Sclerosis Registry (GMSR) including proportions of missing data, adverse events and disease severity scores were used to verify the results on Real-World-Data (RWD).

Indexed as

Multiple SclerosisComputer SimulationHumansData quality controlGrand meanMonitoringMulticenter clinical trialsRegistry data

Identifiers

PMID37450198
PMCPMC10579126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.